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The introduction of the electron microscope to the study of the biological materials in the second half of the last century has dramatically
expanded our view and understanding of the inner workings of cells by enabling the discovery and study of subcellular organelles. A population of
flask-shaped or spherical invaginations of the plasma membrane were described and named plasmalemmal vesicles or caveolae. Until the
discovery of caveolin-1 as their first molecular marker in early 1990s, the study of caveolae was the exclusive domain of electron microscopists
that demonstrated caveolae at different surface densities in most mammalian cells with few exceptions. Electron microscopy techniques in
combination with other approaches have also revealed the structural features of caveolae as well as some of their protein and lipid residents. This
review summarizes the data on the structure and components of caveolae and their stomatal diaphragms.
D 2005 Elsevier B.V. All rights reserved.1. Introduction
Caveolae are subcellular structures that were first described
in 1953 in the continuous endothelium of the heart by G.E.
Palade [1] who called them plasmalemmal vesicles. Two years
later, E. Yamada described similar structures in the gall bladder
epithelium, naming them caveolae intracellulares [2] due to
their resemblance to ‘‘little caves’’. Since their discovery, the
presence of caveolae-like structures has been documented by
electron microscopists in most cell types, with few exceptions
such as red blood cells, platelets, lymphocytes [3], neuroblas-
toma [4] and other neuronal cells and certain epithelia such as
CaCo-2 cells [5].
For approximately four decades, the vast data generated by
electron microscopy in many different cell types banked on a
purely morphological definition of caveolae. In absence of
molecular markers, terms such as caveolae or plasmalemmal
vesicles were used to describe morphological entities that may
or may not correspond to the operational definitions in use
today. The discovery of caveolin-1 as the first molecular0167-4889/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
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E-mail address: Radu.V.Stan@Dartmouth.edu.marker of caveolae [6] has enabled biochemical, cell biological
and genetic approaches with results that have considerably
contributed to our current understanding of these structures.
Based on their lipid composition and biophysical features,
caveolae are considered subtypes of lipid rafts [7] that form
invaginations and are capable of endocytosis [8–11]. What
separates caveolae from other lipid rafts-based invaginations
and endocytotic pathways is the presence of caveolin-1 as a
marker [12–17]. This is the operational definition of caveolae I
will use throughout this paper.
1.1. Morphology of caveolae
Caveolae were morphologically defined as spherical or
flask-shaped invaginations of the plasma membrane of
strikingly regular shape and size (¨70 nm average outer
diameter) [18–20]. Caveolae occur in ordered, linear arrays
over the entire cell body (Fig. 1A) suggesting a link with the
underlying cytoskeleton [21–30]. This link is further enhanced
by the fact that their disposition seems to relate to whether the
cells are migrating or not. In the former, caveolin and caveolae
seem to preferentially distribute to the retracting edge of the
cell [31–33]} (reviewed in [34]). In endothelial cells (ECs)
forming a monolayer in situ, a narrow parajunctional strip of
plasma membrane was found to be devoid of caveolae by
freeze-fracture studies [21].1746 (2005) 334 – 348
http://www
Fig. 1. (A) Endothelium of continuous type as seen by freeze fracture. The P face of the abluminal membrane of a heart EC shows the numerous caveolae. These are
organized in linear arrays, better seen in the higher magnification images (insets). Reproduced from [21], with permission. (B–E) Caveolae with (D–E) and without
(B–C) SDs as seen by TEM (C, E) or in deep-etch specimens (B, D). (B, D) Reproduced from [155] with permission.
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grape-like clusters. In the endothelium, these are attached to
either front of the cell as demonstrated by tridimensional
reconstructions of thin serial sections [1,18–20,35–42]. In
other epithelia, caveolae are preferentially attached to the
basolateral surface such as in MDCK cells and in CaCo2 cells
upon de novo expression of caveolin-1 [43]. In muscle cells
[44,45] or in freshly isolated adipocytes [46], caveolae occur
mostly as single invaginated entities rather than clusters
although these can be found as well.
Endothelial caveolae can adopt several conformations. For
example, single caveolae or caveolae clusters from opposite
fronts can fuse and form occasional transendothelial channels
(TEC) [47]. They are also believed to form intricate clusters
that are open at both fronts of the EC, the so-called vesiculo-
vacuolar organelles (VVO). The VVOs are specialized
structures that occur in either the normal endothelium of the
venules (at steady state or when activated by vasoactive
substances or cytokines) or in the endothelium of solid tumors
[for an extensive review, see [48]).
In fibroblasts differentiated into adipocytes [49,50], in
endothelia [21,51] or in epithelial cells [52], caveolae could
be attached to large, finger-like invaginations of the plasma
membrane that are surrounded by cortical actin. This has led
some investigators to consider them as a novel caveolae based
membrane domain, which was called ‘‘cav-actin’’ [53].
However, a subsequent study showed that these large
invaginations or ‘‘caves’’ have all the attributes of the plasma
membrane proper and caveolae just attach to them at higher
surface density [54]. These structures are also known as
‘‘caveolae rosettes’’ (Fig. 2B) because of the aspect the ‘‘caves’’
and their attached caveolae give in transversal sections by
transmission electron microscopy (TEM) [50]. The caveolar
rosettes seem not occur in freshly isolated adipocytes where
only single invaginated caveolae have been found. It is notclear whether this is due to the maturation stage [46]. The
rosette numbers seem to be increased in endothelial cells upon
overexpression of intersectin, a protein involved in caveolae
endocytosis [55].
1.1.1. Distribution of caveolae
Caveolae occur at different surface densities in different cell
types. Endothelial cells (ECs) are among the richest in caveolae
(Fig. 1A), where these structures were studied the most by EM.
There is marked variation in caveolar surface density within a
given cellular type, which is best exemplified in the case of the
different types of endothelium [21] or mesothelia [56]. In the
endothelium, the largest population of caveolae occurs in the
continuous type (e.g., 89 and 78 vesicular openings per Am2 of
plasma membrane in the heart and skeletal muscle endotheli-
um, respectively), while their numbers are much lower in the
fenestrated endothelium (e.g., 25 and 10 vesicles per Am2 in
jejunum and pancreas, respectively) to occasional caveolae in
the endothelium of discontinuous type [21]. These numbers
were determined in the ECs after aldehyde fixation and were
challenged by findings of reduced caveolar numbers in frozen,
unfixed specimens [57–59], suggesting that fixation might
induce the formation of the invaginations. The caveolae in
frozen tissues were also found to have a slightly larger diameter
that those in fixed tissues.
Adipocytes are also very rich in caveolae, along with,
fibroblasts, muscle and certain epithelial cells. In adipocytes,
¨20% of the plasma membrane was estimated to be caveolar
membrane [49,60].
Decreased numbers of caveolae occur in a number of cell
types upon establishing a primary cell culture. For example,
ECs decrease the numbers of their caveolae in culture one or
more orders of magnitude than in situ, depending on the
endothelium type. The numbers of caveolae (as well as
caveolin-1 levels) are also reduced in oncogenically trans-
Fig. 2. Caveolar coat. Striations have been demonstrated by TEM in smooth muscle (A) and fibroblasts (F). They are readily apparent by either SEM on chromium-
coated replicas of endothelial cells (B) or in platinum-carbon replicas of deeply etched specimens in fibroblasts (C, E–F). The ridges are best seen when caveolae are
flattened by treatment with cholesterol binding drugs (nystatin) (E–F). (F) Immunolocalization of caveolin-1 to the caveolar coat ridges. Reprints from (A) [63], (B)
[27] and (C–F) [6] with permission. B is courtesy of Rob Parton.
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culture).
Morphologically distinguishable caveolae are virtually
absent in cells in suspension while in adherent cell types their
distribution depends on whether the cells are resting or
migrating as noted above.
1.1.2. Caveolar ‘‘coat’’1
Caveolae appear by TEM as smooth, uncoated vesicles,
which is easy to distinguish from the characteristic ‘‘fuzzy’’
appearance of the clathrin-coated vesicles. However, TEM
examination of smooth muscle caveolae [63] has detected
parallel, ¨10 nm thick filaments or ‘‘striations’’ that occur on
their cytoplasmic face (Fig. 2A). High-resolution scanning
electron microscopy (SEM) of critical point dried and
chromium-coated EC plasma membranes has detected ‘‘me-
ridian ridges running between two poles’’ on the cytoplasmic
face of caveolae as well. These ridges were clearly different
from the coat formed by clathrin (see Fig. 2C–D for
comparison) on the cytoplasmic surface of the coated pits
and vesicles [27]. The existence of the ridges on caveolae was
also confirmed by rapid freeze deep-etch techniques in ECs
and fibroblasts in both unfixed and glutaraldehyde fixed cells
[29,64,65]. It is noteworthy that the coat ridges could be
decorated with myosin fragments making them more prom-
inent suggesting the participation of a myosin interacting
molecule (presumably actin) in their structure. In the same
vein, treatment with phalloidin, an actin-stabilizing agent, also
enhanced the ridge appearance. Quite interestingly, the
authors failed to find caveolar ridges on smooth plasma
membrane invaginations in the size range of caveolae in renal
proximal tubule epithelial cells, in hepatocytes as well as in
the urinary bladder epithelium. Here only ‘‘rough surface
invaginations’’ were found [64]. This might mean either that
different subclasses of smooth invaginations exist or that in
different cell types the coat confers special functions to the
invaginations.
Lastly, carbon-platinum deep-etch replicas of fibroblast
plasma membrane sheets showed that the caveolar ridges
formed ‘‘spiral patterns’’ (Fig. 2E, G–I) [6]. The ‘‘coat’’ has
been shown to be resistant to high-salt and high-pH [6]
extraction pointing to the fact that it is not made of peripheral
membrane proteins. Moreover, similar ridge patterns decorate
invaginated caveolae as well as portions of the plasma
membrane with different amounts of curvature (Fig. 2E) [6];
this was taken to indicate caveolae in different stages of
formation supporting the view that these are dynamic structures
[6]. The ridges occupied areas with a diameter of up to 125 nm,
which was especially apparent on flat membranes or on
flattened caveolae. Finally, cholesterol binding drugs such as
nystatin were shown to flatten caveolae and to disassemble the
coat [6] indicating a requirement for cholesterol in their1 The term caveolar ‘‘coat’’ refers to ridges or filaments described to occur on
caveolar invaginations. However, there is no data showing that these ridges
would form a coat resembling those made by the clathrin or COP proteins,
which are thought to assist in the formation of pits and vesicles.structure (Fig. 2G); the fragmentation of the coat resulted in
what appeared ¨10 nm diameter uniform units [66].
Caveolin-1 has been shown to be associated with the
caveolar ridges [6] (Fig. 2H–I). The possible role of the
caveolin proteins in the formation of the coat will be discussed
below.
Besides the deep-etch of rapidly frozen tissues work of
Izumi et al. mentioned above [29,64,65], other studies failed
to detect a striated coat on the cytoplasmic face of
invaginations resembling caveolae (i.e., in size and shape).
Recently, Westerman et al. reported the lack of the coat in
caveolin-1-containing, light membrane vesicles isolated in
presence or absence of Triton X-100 and studied by freeze-
fracture [64,67,68]. Instead, they reported clusters of intra-
membrane particles (IMP) situated most frequently around
the neck of the isolated membrane vesicles. However, it is
not clear how representative for the situation in situ the
isolated membranes are. Especially, the Triton X-100
treatment has been shown to induce modifications of the
composition of the membranes in a considerable body of
literature. Additionally, freeze-fracture would not be a choice
technique for looking at the cytoplasmic face of the caveolae
as it used to obtain details yielded by the fracture of the
cellular membranes in between the two leaflets. In a follow-
up paper, the same group [69] reports that no coat was
detected on the caveolae of unfixed snap frozen fibroblasts.
Lastly, Thorn et al. report that no striated coat was found by
SEM on the caveolae of fixed adipocytes and fibroblasts
[46]. The vesicular profiles examined were deemed caveolae
by caveolin-1 staining.
1.2. Caveolin family of proteins
An important milestone in the caveolae field was achieved
with the demonstration by immunocytochemistry of caveolin
(now caveolin-1) as a specific component of the ridges that
make the caveolar coat [6] (Fig. 2H–I). This has advanced the
operational definition of caveolae to plasma membrane
invaginations that contain caveolins.
Caveolin-1 along with caveolin-2 [70] and caveolinB3 [71]
is part of a gene family well conserved in amniotes. Caveolin-1
and -2 have similar tissue distribution being expressed in most
cell types [28,72–74], while caveolin-3 occurs primarily in
muscle cells [75].
Caveolin-1 is a 22-kDa phosphoprotein that has been
identified as a v-src phosphorylation substrate in Rous Sarcoma
Virus-transformed fibroblasts [76,77] and independently
cloned as VIP21, a component of the trans-Golgi-derived
vesicles [72,78]. Caveolin-1 has two isoforms: caveolin-1a
contains residues 1–178 and caveolin-1h contains residues
32–178. Caveolin-1h is translated from a different mRNA than
caveolin-1a [79,80]. Caveolin-1 is phosphorylated on serine/
threonine sites by PKCa [81–83] and on tyrosines (Tyr14
being the most important) by c-src and possibly other non-
receptor tyrosine kinases [76,84–94]. Tyrosine phosphoryla-
tion seems to occur mainly on caveolin-1a. This last result and
the apparently different distribution of caveolin-1a and -h
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lin-1a and -h) and caveolae with lesser degree of invagination
or flat membranes (containing only caveolin-1h [30] are the
functional differences detected so far between the two
caveolin-1 isoforms.
Caveolin-1 and -3 (but not caveolin-2) are palmitoylated on
three cysteines in the C-terminal region, but the palmitoylation
is not necessary for caveolin targeting to caveolae [95]. In ECs,
the palmitoylation occurs post-translationally and is irrevers-
ible, which is an important difference from other acylated
proteins where palmitoylation is reversible and regulatable
[96–98]. Based on this last data and the demonstration that
palmitoylation stabilizes the caveolin oligomers [99], the
palmitoylation of caveolin has been proposed to have a role
in increasing its membrane association mediated by the
hydrophobic domain [96].
Another feature of the caveolin molecule is the ‘‘scaffolding
domain’’, a region adjacent to the hydrophobic domain used by
caveolins to interact with signal transduction molecules
[100,101]. Unconventional membrane attachment domains
responsible for targeting the molecule to caveolae [101] and
Golgi [102] have been proposed to exist in the caveolin
molecule. However, a recent paper [103] questioned the
existence of a specific targeting domain suggesting that the
disruption of the overall conformation of caveolin molecule
would impair caveolae targeting, raft association and Golgi
exit.
Caveolin-2 has three known isoforms (a, h, g) that were
discovered in adipocytes [70]. Cav 2a is the full-length isoform
whereas 2h is an alternatively spliced isoform that has a
different subcellular distribution than caveolin-2a [104]. The
phosphorylation of caveolin-2 on serines 23 and 36 modulates
caveolin-1-dependent caveolae formation [105]. Caveolin-2 is
also phosphorylated on tyrosine 19 or 27. Phospho-caveolin-2
(pY19) and phospho-caveolin-2 (pY27) display different
cellular localization patterns [106]. Finally, mice lacking
caveolin-2 show severe pulmonary dysfunction but without
disruption of caveolar invaginations [107].
Caveolin-3 [108] is expressed in skeletal muscle and
myocardium where it is essential for the formation of caveolae
[109,110]. It was also shown to be expressed in smooth muscle
cells [111], astrocytes [112] and sinus endothelial cells [113].
Loss of caveolin-3 results in muscle degeneration [109],
cardiomyopathy [114] and increased adipose tissue deposition
[115]. Increased caveolin-3 levels are associated with muscle
dystrophy, cardiomyopathy and cardiac hypertrophy inhibition
[116–118].
For more detailed reviews on caveolins, see [119,120].
1.3. Caveolin-1 and caveolin-3, but not caveolin-2, are
essential for the formation of caveolar invaginations
Several lines of evidence demonstrate the essential role of
caveolin proteins in the structure of caveolae. Caveolin-1
expression in cells lacking both caveolae and caveolin
expression induces caveolae formation [3] and reconstitutes
the caveolar coat [121]. Both caveolin-1a and -h isoforms areable to induce the formation of caveolae de novo, caveolin-1h
being somewhat less efficient [30]. The transfection of
caveolin-1-GFP constructs reconstitutes caveolae but the
striated coat has a clearly different (fuzzy or hairy) appear-
ance, which again suggests caveolin participation in its
structure [122]. De novo expression of caveolin-3 leads to
formation of caveolae. Expression of caveolin-2 alone does
not lead to caveolae formation; in fact, caveolin-2 alone does
not traffic further than Golgi, needing co-transfection of
caveolin-1 in order to reach plasma membrane caveolae
[73,123,124].
The most compelling evidence for the structural role of
caveolin-1 and -3 in the formation of caveolae came from
knockout mice lacking one or both of these proteins [115,125–
127]. It has been shown that upon CAV3 gene loss, the muscle
cells do not have any invaginated profiles resembling caveolae
while they are still present in other cell types [109,110].
Conversely, in CAV1/ mice, the complete lack of caveolae
invaginations is readily seen in ECs, pneumocytes type I,
fibroblasts and adipocytes, to name a few, while they are
present in muscle cells [125,127]. Morphometric analysis of
the endothelia of CAV1/ mice [127] revealed that the
number of coated pits and vesicles apparently free in the
cytoplasm is comparable with wild type littermates (RV Stan
unpublished). Loss of caveolin-2 does not disrupt caveolae
[107], CAV2/ mice having unaltered number of caveolae.
Taken together, these data show that caveolin-1 and caveolin-3
are essential for caveolae formation.
However, larger (100–150 nm) invaginations of the plasma
membrane and vesicle clusters are present in the endothelium
of the venules in the heart and lung of CAV1/ mice
[125,127]. This is a rare occurrence that was detected so far
only in endothelium. This provides genetic evidence that other
smooth invaginations could exist in absence of caveolin-1 and
by our operational definition these invaginations are different
from caveolae.
1.4. Do caveolin proteins participate in the formation of the
‘‘caveolar coat’’?
Caveolin-1 has been shown to be associated with the
caveolar ridges [6] (Fig. 2H–I) where it was proposed to play a
structural part. The data sustaining such a paradigm show that
Caveolins form oligomers, which may form the units of the
coat. All caveolins have a central 33-aminoacid long hydro-
phobic domain that is thought to adopt a hairpin conformation
into the membrane, leaving both N- and C-termini of the
protein facing the cytoplasm [95,128,129]. Caveolin-1 (as well
as caveolinB3) can form homotypic oligomers of up to 18-mer
both in vivo and in vitro [99,100,128] or heterotypic oligomers
with caveolin-2 [73,74]. The oligomers seem to form by
interactions via both the N- and C-terminus domains of
caveolins. Both homo-oligomers of caveolin-1 and hetero-
oligomers involving caveolin-1 and -2 are believed to form the
ridges of the caveolar coat. A recent study using truncation
mutants of caveolin-1, -2 and -3 in combination with negative
staining showed that the N-terminal oligomerization domain is
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units form ¨10 nm diameter particles, which would further
oligomerize and form up to 50 nm filaments. This strengthened
the idea of the ridges being made by units of caveolin
heptamers [66].
The paradigm of caveolin-1 forming the ridges of caveolae
was challenged by several studies that failed to detect a
striated coat on the cytoplasmic face of caveolae invagina-
tions (deemed as caveolae by the presence of caveolin-1
staining) in different cell types [64,67,68]. By freeze-fracture,
Westerman et al. have detected intramembrane particles
(IMPs) staining for caveolin-1 and disposed either as ‘‘rings’’
surrounding the introit of vesicles or localized on their
surface. Please note that the IMPs are thought to represent
membrane proteins [30] and that the freeze-fracture approach
does not obviate the cytoplasmic surface of caveolae and
cannot detect the ridges as it examines the face of each
membrane leaflet situated in the middle of the bilayer. As the
disposition of anti-caveolin-1-associated IMPs was not con-
sistent with caveolin-1 forming the ridges of the coat, it was
postulated that the ‘‘ridges’’ would be formed by actin rather
than caveolins by analogy to a model proposed in yeast [68].
The very fact that anti-caveolin-1 antibodies stained IMPs
apparently clashed with the data of Fujimoto et al. [130], who
have observed in freeze-fractured specimens that the ‘‘shallow
caveolae’’ (i.e., membrane dimples) and the flat membrane
portions decorated by caveolin-1 antibodies were devoid of
IMPs.
Westermann et al. [69] have recently revisited these issues in
cultured, unfixed 3T3-L1 fibroblasts by a freeze-fracture
method published earlier by Fujimoto et al. [130]. Here the
samples are flash frozen (with the aim of avoiding possible
artifacts induced by chemical fixation), fractured, replicated
using platinum/carbon and SDS digested. The latter step
digests the tissue except for the molecules in direct contact
with the platinum/carbon film that can be further immunola-
beled. By using anti-caveolin-1 immunogold labeling of
replicas and stereomicroscopy, the authors showed that
caveolin-1 is disposed as a large belt around the caveolar
invaginations, leaving the polar portion of the invagination
unlabeled. Interestingly, there were no IMPs associated with
caveolin-1 staining in the figures presented, which in part was
probably the result of the lack of platinum layer on the caveolar
body. As the authors conclude, these results are not opposed to
those showing caveolin-1 forming the filamentous coat on the
cytoplasmic face (opposite to the one investigated). This work
also showed that the interaction between cholesterol and
caveolin-1 is necessary to maintain the curved structure of
caveolae, in keeping with the data in the literature showing the
essential role of these molecules in the formation of caveolar
invaginations.
Although these two studies [68,69] bring new insights, there
is a clear limitation to the labeling approach used. The
molecular diameter of IgG is 15 nm, thereby when using two
antibodies (i.e., primary plus reporter) the label might be
associated with any point within a radius of 30 nm. At the size
range of caveolae (or IMPs), this makes the labeling somehowimprecise. A revisiting of these matters with primary antibody
Fab fragments labeled with smaller gold would add more
precision in labeling.
Another study that does not support the model of
caveolin-1 forming a coat on the cytoplasmic face of
caveolae was published by Thorn et al. [46]. They have
looked both by SEM and TEM at plasma membrane sheets
freeze-dried and cryosputtered with tungsten and found again
no striations on caveolae in both fixed freshly isolated
adipocytes and fibroblasts in culture. Caveolin-1 antibodies
stained only a ring around their introit. No caveolin-1 was
found on the vesicle bodies. This method used for specimen
preparation was previously validated mostly on cytoskeletal
preparations where it was shown that it reduces the shrinkage
of the sample as compared to the critical point drying by
avoiding the dehydration step [131–133]. However, there is
no previous report where this method was used for high-
resolution studies on cellular membranes to be used for
comparison. For example, in the images published, an
uneven and thicker coating of the clathrin-coated pits could
be seen, which could obscure the details on caveolae. While
the surface of the adipocyte caveolae appeared very smooth,
that of the fibroblast caveolae looked rougher. This might
mean that the adipocytes caveolae do not have striations (as
Izumi et al. showed before for other cell types by deep-etch)
or they are lost during specimen preparation. Also, a
limitation of the SEM is its relative lower resolution
compared to TEM; the rougher surface seen on fibroblast
caveolae might be the coat that could not be resolved by the
technology used.
Besides the data already discussed, there are data by TEM
and pre and postembedding immunocytochemistry showing
that the caveolins are distributed around the caveolar body
[6,52,72,78,134]. However, each of these studies used second-
ary antibodies as reporters, which raises concerns as to the
precision of staining, as discussed above.
Presently, it is hard to explain the reason for these
apparently diverging results. In exchange for high resolution
achieved, the tissues have to be prepared in a suitable form
for analysis using an electron beam. The sample preparation
step is a problem with all the EM technologies, as we are still
not a hundred percent sure whether its end product is a
faithful representation of the live tissue. Besides many steps
necessary for preparing the membranes for inspection of the
cytoplasmic face used in all the methods mentioned above,
not all the phenomena happening during sample preparation
are completely understood mechanistically. Thus, it is likely
that more data are needed in order to draw definitive
conclusions.
At this point in time, the essential role of caveolins in the
formation of the invaginations is pretty well established. What
is not clear is whether the coat exists on caveolae in all cell
types and if it does, whether caveolins form the filaments of the
coat or not. The modification of the coat appearance upon
caveolin-1-GFP transfection (as seen by rapid-freeze deep-
etch) would be consistent with a structural role of caveolins
forming the caveolar coat. However, these data still do not
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than caveolins (i.e., actin). Although several hypotheses were
advanced such as the coat driving the membrane curvature
[135] and the coat organizing the lipids in the caveolae
microdomain [66], we are far from a clear understanding of its
role. This remains to be investigated by a careful dissection of
the molecular components of caveolae.
1.4.1. Caveolar lipids
Indications of a specific lipid composition of the caveolar
membranes came from EM experiments in different cell types
employing cholesterol-binding probes and showed an enrich-
ment of cholesterol in caveolae [130,136,137]. Subsequent
studies have demonstrated caveolin-1 to bind tightly free-
cholesterol and to bind to artificial phospholipid liposomes
only upon cholesterol incorporation [138–140]. Moreover,
cholesterol is necessary to stabilize caveolin oligomers, both
sterol and protein being necessary to generate and maintain
caveolar structure [99]. These data and the sensitivity of
caveolae architecture to cholesterol depletion [6] and oxidation
[141] have established caveolae as cholesterol-enriched mem-
brane microdomains.
Caveolae are also enriched in sphingolipids (such as
sphingomyelin, ceramide and gangliosides) that occur mostly
in the exoplasmic leaflet of the membrane bilayer, [52,130,137,
141–143]. Caveolin-1 also binds glycosphingolipids (such as
GM1 ganglioside) [144] and fatty acids [145]. The lipid
composition of caveolae (i.e., cholesterol, sphingomyelin,
glycosphingolipids and saturated fatty acids) is similar to that
of ‘‘lipid rafts’’, membrane microdomains that occur in all cell
types [7,146–148].
1.5. Stomatal diaphragms of caveolae
In certain subtypes of endothelial cells, caveolae can be
provided with specialized structures called Stomatal Dia-
phragms (SDs) [18,19,149–154](Figs. 1D–E, 4 and 5)). The
remainder of the review will focus of the structure and
components of SDs.
So far, the SDs have been demonstrated to exist only in
select endothelia of continuous type (i.e., in lung, tongue,
kidney vasa recta) and in all fenestrated and sinusoidal
endothelia. The existence of caveolae with or without stomatal
diaphragms has been clearly demonstrated by rapid-freeze
deep-etch techniques ([58,155] and Fig. 1B–E). By TEM, the
stomatal diaphragm is a thin (¨5–6 nm) protein [156,157]
barrier anchored in the caveolar neck (introit, mouth or
stoma—hence the name), which has a central density or knob.
The SD appears not to have the characteristic trilaminar
structure of the membrane lipid bilayer therefore it is thought
to lipid-free (reviewed in [158]).
Although no formal study has documented the precise
distribution of the stomatal diaphragms, they seem to occur on
endothelial caveolae at both fronts of ECs [18,19,149–154].
Similar diaphragms occur at the stomata (or communication)
between fused caveolae in normal endothelium or the stomata
of the VVOs in the vascular endothelium in tumors and theendothelium of normal venules [159]. By TEM, the caveolar
SD is similar to the diaphragm of transendothelial channels
(TEC), which are pores through the EC body provided with
two SDs, one luminal and one abluminal (Figs. 4 and 5). They
are also similar to the fenestral diaphragms (FDs) that span the
endothelial fenestrae (Figs. 4 and 5) that are circular openings
through the EC body resembling ‘‘boat portholes’’. Fenestrae
seem to have a constant size (¨62–85 nm) and occur in
clusters called ‘‘sieve plates’’ [18,19,21,149,150,156].
1.6. Plasmalemmal vesicle associated protein (PLVAP, gp68,
PV-1, PV1)
Recently, our group has shown that the SDs and FDs share
at least one biochemical marker, namely PV1 [151–154,160]
(Fig. 3). PV1 protein has been discovered as the antigen of a
novel endothelial antibody (21D5 mAb) [161], which co-
localized strictly on endothelial caveolae from rat lung
immunoisolated on anti-caveolin-1 antibodies [134].
PV1 gene product is encoded by Plasmalemmal Vesicle
Associated Protein (symbol PLVAP) gene in humans and its
presence has been clearly documented only in mammals
(Homologene record #10578). ([151–154,160] and unpub-
lished observations). The gene or significant orthologues are
absent from yeast (S. cerevisiae), insects (D. melanogaster)
and nematods (C. elegans) where the SDs and FDs are not
present. No significant orthologue was found in lower
vertebrates such as ascids, amphibians or fish. Thus, PLVAP
genes encode for a family of proteins (Pfam 6637) that are
highly conserved in mammals, consistent with a function in
their cardiovascular system. PV1 mRNA is expressed in most
organs and tissues with the highest levels in lung, kidney,
spleen, all endocrine glands and digestive tract followed by
modest levels in large vessels, heart, skeletal muscle, skin,
brain and testis [151,152,160].
PV1 is a single span, type II membrane glycoprotein that
forms homodimers in situ [151,154,161]. The size of the
monomer is 60 kDa in N-glycosylated, mature form. The N-
linked glycans form ¨15% of the PV1 mass and contain
terminal non-reducing Gal or GalNAc, GlcNAc as well as
sialic acid in both a2–3 and a2–6 linkage [151]. The
monomer has a very basic calculated pI (¨9.1) and the
determined pI of the dimer in glycosylated form is still
shifted to the basic (pI ¨7.8). Thus, it came as no surprise
that rat PV1 binds avidly to heparin at physiological pH
[162].
PV1 has a short (27 aa) intracellular tail and a long (358
aa) extracellular C-terminal domain, topology that was
confirmed with peptide antibodies directed against the C-
terminus [151,152] (schematized in Fig. 5b). The intracellular
domain does not contain any conserved known consensus
site across mammalian species. It contains, however, two
short identical stretches of aminoacids, one next to the
transmembrane domain (8 aa) and the other one at the
extreme N-terminus (7 aa), which might play a role in the
biology of PV1. The conserved domain next to the
transmembrane domain might contain a putative caveolin-1
Fig. 3. Essential role of caveolins in the formation of caveolae. (A) Representative micrograph of heart ventricular endothelial and muscle cells from wild-type mice.
Caveolae are indicated by arrows. (B) In caveolin-1/ mice Caveolae were only found in the skeletal muscle cells (myocardium included) not in other cell types
such as endothelial, smooth muscle, adipocytes, fibroblasts, epithelial etc. (C–D) Larger caveolae-like structures could be occasionally observed in the vessels with
diameters larger than capillaries not surrounded by pericytes or smooth muscle cells. These invaginations feature what seem to be SDs. Clathrin-coated vesicles are
indicated (arrowheads) for size comparison. (E) In caveolin-3/ mice, caveolae are absent from the myocardium. Other structures found in caveolin-1/ mice:
TEC (F), fenestrae with FDs (G), VVOs (H) and fenestrae without FDs (from kidney glomerular capillaries) (I), demonstrating that caveolae are not required for their
formation.
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hydrophobic aa such as Trp, Phe or Tyr) [163]. The
extracellular domain contains four N-glycosylation sites near
the transmembrane domain, a proline-rich region near the
CBterminus and two large coiled-coil domains. The second-
ary structure is predicted to be mostly alpha helical
[151,160], sustained by the presence of two large consensus
coiled-coil domains that are obligate alpha helix formers
[164]. Every seventh aminoacid of the alpha helix of the
coiled-coil domain is hydrophobic, which results in a spiralhydrophobic interface through which one coiled-coil domain
interacts with the hydrophobic interface on the cognate
coiled-coil facilitating the formation of an intermolecular
superhelix [164]. Moreover, seven of the cysteines are
situated within the predicted coiled-coil domains. This would
suggest that the coiled-coil-mediated interaction between two
monomers of a dimer would be ‘‘reinforced’’ by several
disulfide bonds. All these data suggest that PV1 might adopt
a rod-like shape. The fact that the PV1 dimers can be
solubilized in SDS suggests that the putative protein–protein
Table 1
Presence of PV1 correlated with the presence of SDs and FDs in the
cardiovascular system
Continuous Fenestrated Discontinuous
Endocardium + (caveolar SDs) N/A N/A
Large Arteries  N/A N/A
Arterioles ? N/A N/A
Capillaries  (muscle, skin,
myocard)+
(SDs) in lung
+ (SDs of cav,
TEC and FDs)
+ cav SDs
Venules + (SDs of cav,
VVOs)




Large Veins  N/A N/A
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interacting proteins (e.g., other PV1 dimers or other
protein(s)) are non-covalent in nature.
PV1 is expressed in endothelium2, as shown by immuno-
fluorescence with anti-PV1 antibodies [151–154]. PV1 is
restricted to a subset of endothelia such as the capillaries of
the lung, choroid plexus, retina, adrenals, pancreas, intestinal
vili, peritubular capillaries in the kidney, liver and spleen.
PV1 is absent from the large vessels of the lung, aorta, vena
cava and coronary artery as well as capillaries in the heart,
skin, skeletal muscle, intestinal smooth muscle (where
caveolae do not have SDs) and kidney glomerulus (where
fenestrae do not have FDs). All in all, the pattern of
expression of PV1 correlates well with the pattern of
expression of FDs and SDs in situ ([152] and our unpublished
data) as well as in cells in culture [153]. Table 1 details the
presence of PV1 along the vascular tree in the different types
of endothelia.
By immunocytochemistry (Fig. 4), PV1 was found to be
specifically associated with the SDs of caveolae and TEC and
the FDs, at both fronts of ECs [151,152,154], this being the
first demonstration of a protein with such localization. The
label was absent from other microdomains of the ECs as well
as from any other cell type in the organs investigated,
bolstering the claims of endothelial specificity.
1.6.1. PV1 is necessary and sufficient to form SDs and FDs
The data obtained by immunocytochemistry showed that the
SDs and the FDs are biochemically related besides being
morphologically similar. Apart from PV1, there are no data on
other specific components of the diaphragms.
PV1 could function either as a structural component,
function modulator component or both, within these dia-
phragms. Recent data from our laboratory strongly suggest
that PV1 is a key structural component of both the SDs and
FDs, necessary and sufficient for diaphragm expression
[153]. This is based on several lines of evidence: (i) PV1
forms homodimers in situ, as demonstrated by co-transfec-
tion of PV1 tagged with two different epitopes followed by
immunoprecipitation and immunoblotting with anti-tag anti-
bodies [154]; (ii) several PV1 homodimers reside in close
proximity within the same diaphragm as shown by cross-
linking experiments of PV1 carried out in situ in rat lung
and kidneys [154]; (iii) treatment of endothelial cells in2 Two recent papers [162] R. Hnasko, M. McFarland and N. Ben-Jonathan,
Distribution and characterization of plasmalemma vesicle protein-1 in rat
endocrine glands J Endocrinol 175 (2002) 649–61, [165] R. Hnasko and N.
Ben-Jonathan, Developmental regulation of PV-1 in rat lung: association with
the nuclear envelope and limited colocalization with Cav-1 Am. J. Physiol.
Lung Cell Mol Physiol 288 (2005) L275–84. have challenged this claim
suggesting that PV1 occurs in most cell types in lungs and several endocrine
glands studied. The differences most likely lie in the specificity of the
antibodies used. As discussed below, PV1 protein is the antigen recognized by
two classic ‘‘anti-endothelial mAb’’, namely MECA 32 and PAL-E. The data
obtained by several laboratories with these mAbs show it to be endothelial
specific, supporting our data (reviewed in [166] R.V. Stan, Endothelial
diaphragms: nanogates of vascular permeability. Anat Rec In press (2005)).culture, lacking both PV1 and the diaphragms, with reagents
that induce de novo formation of FDs and SDs, up-regulate
PV1 expression. As expected, PV1 could be found in the
newly formed FDs and SDs; (iv) PV1 mRNA silencing
using an siRNA approach, prevented the formation of both
FDs and SDs. Actually, this approach prevented the
formation of fenestrae and TEC as a whole, which suggests
that both TEC and fenestrae require PV1 for their
biogenesis; v) Overexpression of tagged PV1 in either
endothelial cells or non-endothelial cells (e.g. fibroblasts,
COS7, HeLa, HEK293), cell types lacking PV1 expression
and diaphragms, led to the formation of caveolar SDs. This
result shows that either PV1 forms the diaphragms by itself
or the other components of the diaphragms are ubiquitously
expressed (or at least in all the cell types studied), PV1
being the limiting factor [153].
1.6.2. Model of PV1 integration in the diaphragms
Based on the similarity of the stomatal and fenestral
diaphragms and morphological evidence on the structural
modulations of endothelial caveolae, it has been proposed
that the transendothelial channels are born by fusion of
caveolae (single or clusters) from the two fronts of the EC
and the fenestral diaphragms will arise through the collapse
of the transendothelial channels to minimal path length [18–
20]. This view held until differences between the two types
of diaphragms have been found: the diameter of SDs is
variable and usually smaller than that of their fenestral
counterparts (=40 nm vs. ¨60 nm, respectively), which are
considered relatively constant features. The ‘‘general chem-
istry’’ of SDs and FDs seems to differ as well. The SDs of
caveolae and TEC behave the same way, binding lectins and
not binding cationized probes, whereas fenestral diaphragms
do not bind or poorly bind lectins and have a high
concentration of anionic sites conferred by proteoglycans
such as heparin and heparan sulfates [167]. The FDs have
been shown by photographic augmentation of grazing TEM
sections or freeze fracture replicas to have an octagonal
symmetry [168]. This was later confirmed in an excellent
paper [155] showing that, in rapidly frozen deep-etched
specimens, the organization of the FDs consists of radial
fibrils anchored in the fenestral rim and interweaving in a
central mesh (the equivalent of the central knob in TEM).
Fig. 4. Immunolocalization of PV1 by immunodiffusion to SDs of caveolae in lung (A–B, E), SDs of TEC (D–E) and FDs (C–D, F), as detected with anti-PV1
antibodies directed against its C-terminus. (A–B) lung, (C–E) kidney, (F) intestine. The label was found specifically associated with the SDs and FDs at both
fronts of the cell. No label was found on the plasmalemma proper, clathrin-coated pits and vesicles, intercellular junctions as well as non-endothelial cellular types.
Bars 100 nm.
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resolved in the same detail due to their smaller size and
technical limitations (i.e., angle of metal shadowing) [155].
What was readily apparent was that the caveolar diaphragms
resembled those of the TEC both featuring a central particle
[155]. However, close inspection of the stomatal diaphragms
reveals hints of a radial pattern very much alike the one of
the fenestral diaphragms.
Based on our data and the data in the literature, we have
formulated a working hypothesis, which is depicted in Fig.
5D. By this, both SDs and FDs consist of a common
framework of radial fibrils inserted in the rim of a pore (i.e.,
caveolar or TEC introit or fenestral pore) and interweaving
in the center of the diaphragm (Fig. 5D). The fibrils would
consist of PV1 dimers whose C-termini would form the
central density of the diaphragm [160]. The dimers could be
‘‘kept afloat’’ by the heavy (¨15% of the PV1 mass)
glycosylation that occurs nearby the membrane (Fig. 5C).
The diaphragm structure could be stabilized via interactions
between PV1 C-termini themselves or with another putative
diaphragm stabilizing extracellular protein. Alternatively, or
in addition to, the diaphragm could be stabilized by the
existence of a rigid structure on the cytoplasmic face of the
rim presumably connected to the cytoskeleton. This latter
assumption seems to be sustained by data obtained with
affinity chromatography and yeast two-hybrid screening
using the intracellular domain of PV1, by which assays
cytoskeletal linker molecules interact with PV1 (R.V. Stan,
unpublished observations).
The HSPGs could interfere with the binding of the lectins
in fenestrae, from where the lack of binding [157] of lectins
by fenestrae. PV1 binds most of the lectins that were shown
to bind to the SDs [157] (e.g. WGA, GS I, RCA,
Concanavalin A, etc.) [151] and unpublished data). Regard-ing the lack of anionic sites on SDs, PV1 protein backbone
has a highly basic pI (¨9.0). Even with the glycosylation,
the pI of the native protein is still slightly basic (¨7.8)
[151], which explains the absence of binding of cationized
ferritin [156,167] by the SDs of caveolae and TEC. Since
caveolae are dynamic structures, it is conceivable that the
protein lifetime is too short for binding circulating HSPGs.
The presence of the HSPGs on the luminal side of
fenestrae could be explained by the following possibilities:
(i) the caveolae from the opposite fronts of the ECs fuse and
form TEC that collapse to the minimal path length and form
fenestrae; the HSPGs on fenestrae are a filtration residue or
(ii) a different biogenetic pathway between fenestrae and
caveolae with the HSPGs as a filtration residue or (iii) a
different biogenetic pathway between fenestrae and caveolae
by which HSPGs are specifically targeted to the fenestral
pore. The existence of TEC, fenestrae and VVOs in caveolin-
1/ animals in absence of caveolae, invalidates the first
hypothesis.
Undoubtedly, most of this paradigm awaits experimental
confirmation. What the data have proven so far is that PV1
is present into both SDs and FDs and that it is necessary
for diaphragm formation, the case being stronger for the
SDs.
1.6.3. Future directions
Undoubtedly our understanding of caveolae and their
stomatal diaphragms has greatly advanced in the last 15
years. However, there are many outstanding questions and
there is still controversy starting with their structure, specific
components and ending with their ascribed functions. From
a structural point of view, we still do not know whether
other specific components of caveolae exist in addition to
caveolins. We do not know what are the components and
Fig. 5. Working model for PV1 integration in the structure of the diaphragms. (A) Perpendicular TEM sections of a caveola provided with SD (left), TEC (middle)
and fenestra (right). (B) En face views of SDs (left) and FDs (right), as shown by deep-etch rapid freeze techniques, demonstrating the fibrils in the FDs and the hints
of fibrils in their SDs counterparts. Reprinted from Bearer and Orci, JCB, 1985, with permission. (C) Schematic of the membrane insertion and features of the PV1
monomer. (D) Model of PV1 integration in the endothelial diaphragms. Left panel: PV1 dimers participate in the formation of the fibrils inserted in the rim (via PV1
N-terminus) and interweaving in the central mesh (via PV1 C terminus). The glycan antennae (accounting for ¨15% of PV1 mass) are situated near the membrane,
which would keep the protein ‘‘afloat’’ by preventing collapse on the plasma membrane. The sharp angle formed by the plasma membrane at the level of the rim is
maintained by ‘‘scaffold proteins’’ that can be either transmembrane or associated with the cytosolic face of the membrane. Right panels: PV1 dimer seen from the
top (up) and in a section perpendicular on the diaphragm plane (bottom).
R.V. Stan / Biochimica et Biophysica Acta 1746 (2005) 334–348344the role of the caveolar ‘‘coat’’ and what drives the
invagination of caveolae. As for the stomatal diaphragms
of caveolae, one wonders whether other components might
play a role besides PV1 as well as what is the function of
the diaphragms altogether. With the increasing availability of
novel and better tools (i.e., functional probes, genetically
engineered animals) to study these problems, the answers
should come in the near future.Acknowledgement
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